PDSB vs. INZY, TNXP, LIMN, CADL, PVLA, DBVT, SGMT, IMMP, ACB, and NGNE
Should you be buying PDS Biotechnology stock or one of its competitors? The main competitors of PDS Biotechnology include Inozyme Pharma (INZY), Tonix Pharmaceuticals (TNXP), Liminatus Pharma (LIMN), Candel Therapeutics (CADL), Palvella Therapeutics (PVLA), DBV Technologies (DBVT), Sagimet Biosciences (SGMT), Prima BioMed (IMMP), Aurora Cannabis (ACB), and Neurogene (NGNE). These companies are all part of the "pharmaceutical products" industry.
PDS Biotechnology vs. Its Competitors
PDS Biotechnology (NASDAQ:PDSB) and Inozyme Pharma (NASDAQ:INZY) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.
Inozyme Pharma is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.
PDS Biotechnology currently has a consensus price target of $9.00, suggesting a potential upside of 625.81%. Inozyme Pharma has a consensus price target of $11.75, suggesting a potential upside of 193.75%. Given PDS Biotechnology's stronger consensus rating and higher possible upside, research analysts plainly believe PDS Biotechnology is more favorable than Inozyme Pharma.
26.8% of PDS Biotechnology shares are owned by institutional investors. Comparatively, 88.3% of Inozyme Pharma shares are owned by institutional investors. 9.2% of PDS Biotechnology shares are owned by insiders. Comparatively, 12.2% of Inozyme Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
PDS Biotechnology's return on equity of -150.59% beat Inozyme Pharma's return on equity.
PDS Biotechnology has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500. Comparatively, Inozyme Pharma has a beta of 2.27, meaning that its share price is 127% more volatile than the S&P 500.
In the previous week, PDS Biotechnology had 1 more articles in the media than Inozyme Pharma. MarketBeat recorded 4 mentions for PDS Biotechnology and 3 mentions for Inozyme Pharma. Inozyme Pharma's average media sentiment score of 0.95 beat PDS Biotechnology's score of 0.14 indicating that Inozyme Pharma is being referred to more favorably in the news media.
Summary
PDS Biotechnology beats Inozyme Pharma on 9 of the 14 factors compared between the two stocks.
Get PDS Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for PDSB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PDSB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PDS Biotechnology Competitors List
Related Companies and Tools
This page (NASDAQ:PDSB) was last updated on 7/11/2025 by MarketBeat.com Staff
Free PDSB Stock Alerts